The effect of strontium ranelate on serum insulin like growth factor-1 and leptin levels in osteoporotic post-menopausal women: a prospective study

Arch Gynecol Obstet. 2008 Nov;278(5):437-41. doi: 10.1007/s00404-008-0611-x. Epub 2008 Mar 6.

Abstract

Objective: The aim of this study was to investigate the effects of strontium ranelate on insulin like growth factor-1 (IGF-1), leptin and osteocalcin levels in osteoporotic post-menopausal women.

Study design: Thirty-three women were given 2 g/day strontium ranelate for 6 months. Serum IGF-1, leptin and osteocalcin levels were measured before and after the treatment.

Results: Strontium ranelate treatment increased IGF-1 levels significantly (P = 0.02). Leptin and osteocalcin levels did not change significantly before and after the treatment. There was no correlation between basal and 6-months treatment levels of IGF-1 and leptin.

Conclusion: Strontium ranelate increases serum IGF-1 levels in osteoporotic post-menopausal women.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Body Mass Index
  • Bone Density
  • Bone Density Conservation Agents / pharmacology*
  • Bone Density Conservation Agents / therapeutic use
  • Female
  • Follow-Up Studies
  • Humans
  • Insulin-Like Growth Factor I / metabolism*
  • Leptin / blood*
  • Middle Aged
  • Organometallic Compounds / pharmacology*
  • Organometallic Compounds / therapeutic use
  • Osteocalcin / blood
  • Osteoporosis, Postmenopausal / blood*
  • Osteoporosis, Postmenopausal / drug therapy
  • Prospective Studies
  • Thiophenes / pharmacology*
  • Thiophenes / therapeutic use

Substances

  • Bone Density Conservation Agents
  • Leptin
  • Organometallic Compounds
  • Thiophenes
  • strontium ranelate
  • Osteocalcin
  • Insulin-Like Growth Factor I